Evidence map›Paper›PMID 38042944›Full record

ArticleScientific reports2023

Determinants of exposure to acrylamide in European children and adults based on urinary biomarkers: results from the "European Human Biomonitoring Initiative" HBM4EU participating studies.

Sandra F Fernández, Michael Poteser, Eva Govarts, Olga Pardo, Clara Coscollà, Thomas Schettgen, Nina Vogel, Till Weber, Aline Murawski, Marike Kolossa-Gehring and 26 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 18 institutions in 11 countries.

Sandra F FernándezFoundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, Spain.
Michael PoteserCenter for Public Health, Department of Environmental Health, Medical University of Vienna, Vienna, Austria.
Eva GovartsVITO Health, Flemish Institute for Technological Research (VITO), Mol, Belgium.
Olga PardoPublic Health Directorate of Valencia, Av. Catalunya, 21, 46020, Valencia, Spain.
Clara CoscollàFoundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, Spain.
Thomas SchettgenInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Nina VogelGerman Environment Agency (UBA), Dessau-Roßlau, Berlin, Germany.
Till WeberGerman Environment Agency (UBA), Dessau-Roßlau, Berlin, Germany.
Aline MurawskiGerman Environment Agency (UBA), Dessau-Roßlau, Berlin, Germany.
Marike Kolossa-GehringGerman Environment Agency (UBA), Dessau-Roßlau, Berlin, Germany.
Maria RütherGerman Environment Agency (UBA), Dessau-Roßlau, Berlin, Germany.
Phillipp SchmidtGerman Environment Agency (UBA), Dessau-Roßlau, Berlin, Germany.
Sónia NamoradoDepartment of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
An Van NieuwenhuyseLaboratoire National de Santé (LNS), 3555, Dudelange, Luxembourg.
Brice AppenzellerHuman Biomonitoring Research Unit, Department of Precision Health, Luxembourg Institute of Health (LIH), 1 A-B, Rue Thomas Edison, 1445, Strassen, Luxembourg.
Kristín ÓlafsdóttirDepartment of Pharmacology and Toxicology, University of Iceland, Reykjavík, Iceland.
Thorhallur I HalldorssonFaculty of Food Science and Nutrition, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Line S HaugNorwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway.
Cathrine ThomsenNorwegian Institute of Public Health, Lovisenberggata 8, 0456, Oslo, Norway.
Fabio BarboneDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Ospedale di Cattinara, Strada di Fiume 447, 34149, Trieste, Italy.
Marika MariuzCentral Directorate for Health, Social Policies and Disability, Friuli Venezia Giulia Region, Riva Nazario Sauro, 8, 34124, Trieste, Italy.
Valentina RosolenCentral Directorate for Health, Social Policies and Disability, Friuli Venezia Giulia Region, Riva Nazario Sauro, 8, 34124, Trieste, Italy.
Loïc RambaudSanté Publique France, SpFrance, 12, Rue du Val d'Osne, 94415, Saint-Maurice, France.
Margaux RiouSanté Publique France, SpFrance, 12, Rue du Val d'Osne, 94415, Saint-Maurice, France.
Thomas GöenInstitute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054, Erlangen, Germany.
Stefanie NüblerInstitute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054, Erlangen, Germany.
Moritz SchäferInstitute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054, Erlangen, Germany.
Karin H A ZarrabiInstitute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054, Erlangen, Germany.
Ovnair SepaiUK Health Security Agency, London, SE1 8UG, UK.
Laura Rodriguez MartinVITO Health, Flemish Institute for Technological Research (VITO), Mol, Belgium.
Greet SchoetersVITO Health, Flemish Institute for Technological Research (VITO), Mol, Belgium.
Liese GillesVITO Health, Flemish Institute for Technological Research (VITO), Mol, Belgium.
Karin LeanderUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Nobels Väg 13, Box 210, 17177, Stockholm, Sweden.
Hanns MoshammerCenter for Public Health, Department of Environmental Health, Medical University of Vienna, Vienna, Austria.
Agneta AkessonUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Nobels Väg 13, Box 210, 17177, Stockholm, Sweden.
Federica LaguzziUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Nobels Väg 13, Box 210, 17177, Stockholm, Sweden. federica.laguzzi@ki.se.
German Environment Agency · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEFlemish Institute for Technological Research · BEKarolinska Institutet · SEFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESMedical University of Vienna · ATNorwegian Institute of Public Health · NORegione Autonoma Friuli Venezia GiuliaSanté Publique France · FRUniversity of Iceland · ISGeneralitat Valenciana · ESLaboratoire National de Santé · LULuxembourg Institute of Health · LUOspedale di Cattinara · ITRWTH Aachen University · DEUK Health Security AgencyUniversidade Nova de Lisboa · PTUniversity of Antwerp · BE

Funding

European Union Horizon-2020 733032Research Council of Norway 268465Research Council of Norway 275903
6 · The paper itself

Abstract

Little is known about exposure determinants of acrylamide (AA), a genotoxic food-processing contaminant, in Europe. We assessed determinants of AA exposure, measured by urinary mercapturic acids of AA (AAMA) and glycidamide (GAMA), its main metabolite, in 3157 children/adolescents and 1297 adults in the European Human Biomonitoring Initiative. Harmonized individual-level questionnaires data and quality assured measurements of AAMA and GAMA (urine collection: 2014-2021), the short-term validated biomarkers of AA exposure, were obtained from four studies (Italy, France, Germany, and Norway) in children/adolescents (age range: 3-18 years) and six studies (Portugal, Spain, France, Germany, Luxembourg, and Iceland) in adults (age range: 20-45 years). Multivariable-adjusted pooled quantile regressions were employed to assess median differences (β coefficients) with 95% confidence intervals (95% CI) in AAMA and GAMA (µg/g creatinine) in relation to exposure determinants. Southern European studies had higher AAMA than Northern studies. In children/adolescents, we observed significant lower AA associated with high socioeconomic status (AAMA:β =  - 9.1 µg/g creatinine, 95% CI - 15.8, - 2.4; GAMA: β =  - 3.4 µg/g creatinine, 95% CI - 4.7, - 2.2), living in rural areas (AAMA:β =  - 4.7 µg/g creatinine, 95% CI - 8.6, - 0.8; GAMA:β =  - 1.1 µg/g creatinine, 95% CI - 1.9, - 0.4) and increasing age (AAMA:β =  - 1.9 µg/g creatinine, 95% CI - 2.4, - 1.4; GAMA:β =  - 0.7 µg/g creatinine, 95% CI - 0.8, - 0.6). In adults, higher AAMA was also associated with high consumption of fried potatoes whereas lower AAMA was associated with higher body-mass-index. Based on this large-scale study, several potential determinants of AA exposure were identified in children/adolescents and adults in European countries.

Indexed as

AcrylamideBiological MonitoringAdolescentAdultBiomarkersChildChild, PreschoolCreatinineEpoxy CompoundsHumansMiddle AgedSurveys and QuestionnairesYoung AdultAcrylamideBiomarkersCreatinineEpoxy Compoundsglycidamide

Identifiers

PMID38042944
PMCPMC10693547
OpenAlexW4389270836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.